These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6092738)

  • 21. [Cefotetan, a new cephamycin antibiotic: in vitro and in vivo antibacterial activities (author's transl)].
    Yano K; Suzaki K; Saito M; Toda M; Naito S; Ohmi Y
    Jpn J Antibiot; 1982 Feb; 35(2):438-59. PubMed ID: 6953260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
    Werner H; Heizmann W; Luft G
    Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaerobic bacteria isolated from foot infections in diabetic patients: in vitro susceptibility to nine antibiotics.
    Ginunas VJ; Canawati HN; Sapico FL
    Clin Ther; 1984; 6(4):457-60. PubMed ID: 6467279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative antibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):550-1. PubMed ID: 2548866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of moxalactam against anaerobic bacteria.
    Gilchrist MJ; Washington JA
    Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Apr; 32(4):601-4. PubMed ID: 3163908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The in vitro responses of Bacteroides fragilis to Moxalactam, Cefotaxime, Cefmetazole, Josamycin and erythromycin.
    Soriano F; Ponte MC; Gaspar MC
    J Clin Pathol; 1982 Oct; 35(10):1166-7. PubMed ID: 6290543
    [No Abstract]   [Full Text] [Related]  

  • 28. Antimicrobial activity of SMAP-29 against the Bacteroides fragilis group and clostridia.
    Arzese A; Skerlavaj B; Tomasinsig L; Gennaro R; Zanetti M
    J Antimicrob Chemother; 2003 Sep; 52(3):375-81. PubMed ID: 12917245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of the effect of a cephamycin antibiotic agent, cefmetazole, for the postoperative infections (author's transl)].
    Jpn J Antibiot; 1981 Sep; 34(9):1211-34. PubMed ID: 6948969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of four antibiotics in anaerobic pulmonary infection. An experimental model in rabbits.
    Chandrasekar PH; Rolston KV; Chokkavelu V; Le Frock JL; Kannangara DW
    Chemotherapy; 1984; 30(5):331-6. PubMed ID: 6488936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Laboratory and clinical studies of cefmetazole in serious infection by Staphylococcus (author's transl)].
    Motohiro T; Sakata Y; Fujimoto T; Nishiyama T; Ishimoto K; Tominaga K; Yamashita F; Onoda Y; Kusayanagi T; Tsuboi M; Toubo Y; Yamamoto M; Komatsu R; Tanaka C; Baba Y
    Jpn J Antibiot; 1982 Mar; 35(3):821-34. PubMed ID: 6954289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Laboratory and clinical studies of flomoxef].
    Nozue N; Ueda Y; Haga T; Muraoka A; Ono Y; Nishiya H; Miyashita H
    Jpn J Antibiot; 1987 Oct; 40(10):1774-86. PubMed ID: 3327964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the in-vivo efficacy of Sch 34343.
    Loebenberg D; Moss EL; Rudeen J; Menzel F; Hare RS; Oden EM; Lin CC; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():207-18. PubMed ID: 3897173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibility of anaerobic bacteria to cefoxitin (author's transl)].
    Freydière AM; Gille Y; Marcel JP; Vincent P
    Sem Hop; 1980 Nov 18-25; 56(43-44):1793-5. PubMed ID: 6256880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibacterial activity of cefoperazone against anaerobic bacteria (author's transl)].
    Imamura H; Kobayashi T; Murata K; Kohbata S; Watanabe I; Marui T; Watanabe K; Ninomiya K; Ueno K; Suzuki S
    Jpn J Antibiot; 1980 Nov; 33(11):1171-82. PubMed ID: 6454011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro activity of cefotaxime on anaerobes (author's transl)].
    Soussy CJ; Thibault M; Duval J
    Nouv Presse Med; 1981 Feb; 10(8):556-8. PubMed ID: 6259592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
    Noel AR; Bowker KE; Macgowan AP
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility testing of anaerobes with Etest.
    Bolmström A
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S367-70. PubMed ID: 8324149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.